Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373344 · ClinicalTrials.gov registry record · NA
Remediation of Emotional Processing Deficits in MS
A NA study, sponsored by Kessler Foundation.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT03373344: Completed NA study, sponsored by Kessler Foundation.
NCT03373344 is a NA study that has completed, run by Kessler Foundation. The registered enrollment target is 39 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03373344, a NA study, has completed, sponsored by Kessler Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study will test the effectiveness of an emotional processing intervention in individuals with MS in a double blind placebo controlled randomized clinical trial. We will utilize an intervention which has been successfully used in other populations, including Schizophrenia and Traumatic Brain Injury. Our pilot data shows that this intervention is effective in individuals with MS as well
Primary Outcome
Change in scores on computerized tests of emotional processing
Interventions
- BEHAVIORAL Placebo control exercises
- BEHAVIORAL Emotional Processing Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-11 |
| Est. Completion | 2020-03 |
| Phase | NA |
What the finished NCT03373344 record still lists
NCT03373344 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo control exercises is the first listed.
NCT03373344 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03373344 about?
NCT03373344 is a clinical study titled "Remediation of Emotional Processing Deficits in MS". This study will test the effectiveness of an emotional processing intervention in individuals with MS in a double blind placebo controlled randomized clinical trial. We will utilize an intervention which has been successfully used in other populations, including Schizophrenia and Traumatic Brain Inj...
What is the current status of trial NCT03373344?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2016-11. Estimated completion is 2020-03.
What interventions are being tested in trial NCT03373344?
The interventions under investigation include: Placebo control exercises (BEHAVIORAL), Emotional Processing Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT03373344?
This trial is sponsored by Kessler Foundation, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03373344's enrollment target sits among peer trials
39 1536th of 2000 higher than 463 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia